Zimbabwe has rejected a major American health deal worth $367m (272 million pounds) spanning five years because of Washington's demand for confidential biological samples.
The decision came to light following a government memo dated December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
An official representative later stated that the United States was seeking biological samples for research and profit while was unwilling to guarantee the resulting advantages from future vaccines.
"We will now turn to the difficult and regrettable task of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further negotiations to find a agreement acceptable to both sides so the nation's critical HIV treatment initiative can proceed.
Wider Context
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a high court suspended a similar health funding agreement after concerns were filed about the security of citizens' health data.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the US government, but Trump claimed its expenditure was "inefficient" and his administration was seeking government-to-government deals to boost transparency and accountability.
According to reports, 16 African countries have so far agreed to similar health pacts, representing over $18.3bn in committed funds.
Details of the Declined Deal
The funds for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership could have provided significant benefits for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, without any corresponding promise of benefiting from any medical innovations – like new medicines or tests – that could be developed from that provided information," he stated.
"Put simply, our nation would provide the raw materials for medical research without any certainty that the resulting innovations would be accessible to our people if a future health crisis arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its push of one-on-one health agreements were upending systems already set up through the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing system created to manage potential pandemics.
"This framework is designed to ensure that when a country contributes its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage further discussions with our US partners on how future co-operation might be arranged in a manner that honours the sovereignty and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but suggested that negotiations must proceed since much of the country's Aids initiatives were funded by external financing.
"Where specific concerns arise, such as those involving data governance or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," the group commented.
The halted deal emphasises the continuing challenges between receiving vital foreign assistance and safeguarding a country's data in an ever more data-driven world.